Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden · Delayed Price · Currency is SEK 3.280
-0.020 (-0.61%)
Sep 2, 2026, 5:29 PM CET
Sprint Bioscience AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 93.26 | 126.7 | 25.06 | 49.93 | 29.49 | 70.64 |
Cash & Short-Term Investments | 93.26 | 126.7 | 25.06 | 49.93 | 29.49 | 70.64 |
Cash Growth | 278.24% | 405.68% | -49.82% | 69.31% | -58.25% | 160.92% |
Accounts Receivable | - | 0 | 0.24 | 0.8 | 0.01 | 0.02 |
Other Receivables | 7.33 | 6.16 | 11.95 | 7.14 | 5.38 | 5.28 |
Receivables | 7.33 | 6.17 | 12.19 | 7.94 | 5.39 | 5.29 |
Total Current Assets | 100.6 | 132.87 | 37.24 | 57.87 | 34.88 | 75.94 |
Property, Plant & Equipment | 3.63 | 3.74 | 4.72 | 4.38 | 2.37 | 2.99 |
Long-Term Investments | - | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
Other Long-Term Assets | 0.06 | 0.01 | 0.05 | 0.08 | 0.12 | 0.16 |
Total Assets | 104.28 | 136.66 | 42.06 | 62.38 | 37.42 | 79.14 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.66 | 4.4 | 5.44 | 5.71 | 3.73 | 2.92 |
Accrued Expenses | - | 4.84 | 4.7 | 3.37 | 4.43 | 4.54 |
Current Unearned Revenue | - | - | 11.23 | 12.32 | - | - |
Other Current Liabilities | 10.54 | 8.24 | 11.42 | 13.21 | 1.07 | 1.22 |
Total Current Liabilities | 14.2 | 17.48 | 32.78 | 34.6 | 9.23 | 8.68 |
Total Liabilities | 14.2 | 17.48 | 32.78 | 34.6 | 9.23 | 8.68 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 7.07 | 7.07 | 6.98 | 6.98 | 6.98 | 3.98 |
Additional Paid-In Capital | 291.75 | 291.75 | 273.67 | 273.9 | 273.87 | 258.97 |
Retained Earnings | -208.74 | -179.65 | -271.38 | -253.1 | -252.67 | -192.5 |
Shareholders' Equity | 90.08 | 119.18 | 9.27 | 27.77 | 28.19 | 70.45 |
Total Liabilities & Equity | 104.28 | 136.66 | 42.06 | 62.38 | 37.42 | 79.14 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 93.26 | 126.7 | 25.06 | 49.93 | 29.49 | 70.64 |
Net Cash Growth | 278.24% | 405.68% | -49.82% | 69.31% | -58.25% | 313.73% |
Net Cash Per Share | 0.90 | 1.37 | 0.36 | 0.72 | 0.70 | 2.45 |
Filing Date Shares Outstanding | 108.05 | 105.52 | 69.82 | 69.82 | 69.8 | 39.84 |
Total Common Shares Outstanding | 108.05 | 105.52 | 69.82 | 69.82 | 69.8 | 39.84 |
Working Capital | 86.4 | 115.39 | 4.46 | 23.27 | 25.65 | 67.25 |
Book Value Per Share | 0.83 | 1.13 | 0.13 | 0.40 | 0.40 | 1.77 |
Tangible Book Value | 90.08 | 119.18 | 9.27 | 27.77 | 28.19 | 70.45 |
Tangible Book Value Per Share | 0.83 | 1.13 | 0.13 | 0.40 | 0.40 | 1.77 |
Machinery | - | 11.05 | 10.96 | 9.66 | 7.21 | 7.21 |